Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Trimeris |
---|---|
Information provided by: | Trimeris |
ClinicalTrials.gov Identifier: | NCT00048217 |
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: T-1249 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | T1249-105 |
Study First Received: | October 28, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00048217 |
Health Authority: | United States: Food and Drug Administration |
Treatment Experienced |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |